|
|
Vol. 27.06 – 27 April, 2026
|
|
|
|
|
|
|
|
|
Researchers revealed that venetoclax treatment during ex vivo expansion of CART cells, prepared from T cells from healthy donors or chemotherapeutically pretreated patients, potently augments antitumor efficacy in a BCL-2-dependent manner. [Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists developed a neutrophil-specific modified RNA translation platform, termed NeuSMRT, that enables the expression of CARs in primary neutrophils. In a syngeneic glioma model, CAR-neutrophils produced in vivo significantly inhibited tumor growth and prolonged survival. [Nature Biomedical Engineering]
|
|
|
|
|
|
Investigators hypothesized that targeting CD2, a pan–T-cell antigen, with anti-CD2 CAR T cells engineered to lack CD2 expression would improve manufacturability and preclinical efficacy.
[Blood]
|
|
|
|
|
|
The authors introduced an optimal transport-based framework designed to predict responses to CAR expression at the single-cell level, including variants that have not been experimentally tested. [Cell Systems]
|
|
|
|
|
|
Scientists generated CAR T cells based on natural ligand granzyme B (GrB-CAR T) targeting membrane-bound HSP70. GrB-CAR T cells exhibit potent cytotoxicity against a broad spectrum of cancer cell lines and stem-like cancer cells in vitro.
[Oncogene]
|
|
|
|
|
|
Researchers developed the KCL-Microbioreactor, a closed microbioreactor platform based on microfluidic principles. They demonstrated the platform’s utility by generating functional CAR-regulatory T cells targeting HLA-A2. [IScience]
|
|
|
|
|
|
|
|
The authors discuss different CAR-engineered immune cells for therapeutic applications by highlighting how unique immune attributes, along with cell-specific manufacturing strategies and CAR designs, address challenges faced by conventional CAR-T cell therapy.
[Nature Reviews Bioengineering]
|
|
|
|
|
|
Scientists focus on current in vivo CAR T delivery strategies, including viral vectors and nonviral systems, with a focus on how these platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer. [Cancer Research]
|
|
|
|
|
|
Investigators summarize advancements in CAR-T therapy for solid tumors, including lung, pancreatic, and breast cancer. They discuss major barriers to CAR-T application in solid tumors, including antigen heterogeneity, the lack of specific targets, CAR-T cell exhaustion, and physical barriers within tumor tissues. [Cancer Gene Therapy]
|
|
|
|
|
|
|
|
Dr. Heyang Zhang is developing a safer and more scalable way to reprogramme T cells for CAR T-cell therapy, with the aim of making these treatments more widely accessible.
[Leiden University]
|
|
|
|
|
|
The Center for Cancer and Blood Disorders (CCBD) announced it has launched a new program to deliver CAR-T cell therapy to patients in the Maryland area. [CCBD]
|
|
|
|
|
|
|
|
May 31-June 5, 2026 Barga, Italy
|
|
|
|
|
|
|
|
|
|
|
Medical University of Vienna – Vienna, Austria
|
|
|
|
|
|
|
The Icahn School of Medicine at Mount Sinai – New York City, New York, United States
|
|
|
|
|
|
|
University of Montreal – Montreal, Quebec, Canada
|
|
|
|
|
|
|
University of Virginia – Charlottesville, Virginia, United States
|
|
|
|
|
|
|
Stanford University – Stanford, California, United States
|
|
|
|
|
|